CS MEDICA a/s financials
CS MEDICA a/s
549300SC8KWO7JFWLN17 | Line item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Income statement | |||
| Revenue | DKK 8.1M | DKK 1.1M | — |
| Gross profit | DKK 2.8M | DKK 913.5K | — |
| Other income | DKK 0 | DKK 164.9K | — |
| Administrative expenses | DKK 2.4M | DKK 4.3M | — |
| Employee benefits expense | DKK 8.7M | DKK 8.0M | — |
| Depreciation & amortisation | DKK 2.1M | DKK 2.1M | — |
| Operating profit (EBIT) | -DKK 12.5M | -DKK 17.9M | — |
| Net finance income / (cost) | -DKK 1.5M | -DKK 568.1K | — |
| Profit before tax | -DKK 14.5M | -DKK 18.5M | — |
| Income tax expense | -DKK 4.8M | -DKK 4.0M | — |
| Profit for the year | -DKK 9.7M | -DKK 14.5M | — |
| Total comprehensive income | -DKK 16.0M | -DKK 14.5M | — |
| Per share | |||
| Basic EPS | DKK -0.85 | DKK 0.12 | — |
| Diluted EPS | DKK -0.78 | DKK 0.12 | — |
| Cash flow statement | |||
| Net cash from operating activities | -DKK 4.4M | -DKK 8.3M | — |
| Net cash from investing activities | -DKK 3.4M | -DKK 2.2M | — |
| Net cash from financing activities | DKK 7.3M | DKK 7.2M | — |
| Balance sheet | |||
| Total assets | DKK 36.4M | DKK 25.9M | DKK 27.4M |
| Non-current assets | DKK 31.3M | DKK 21.2M | DKK 13.1M |
| Current assets | DKK 5.1M | DKK 4.7M | DKK 14.3M |
| Trade & other receivables | DKK 3.9M | DKK 2.5M | DKK 1.6M |
| Cash & equivalents | DKK 17.7K | -DKK 415.0K | DKK 10.0M |
| Total equity | DKK 6.0M | DKK 10.4M | DKK 24.1M |
| Non-current liabilities | DKK 13.4M | DKK 8.6M | DKK 1.6M |
| Long-term borrowings | DKK 537.4K | DKK 489.1K | DKK 1.3M |
| Current liabilities | DKK 16.9M | DKK 6.9M | DKK 1.6M |
| Short-term borrowings | DKK 813.1K | DKK 0 | DKK 0 |
| Current portion of long-term borrowings | DKK 3.7M | DKK 192.0K | DKK 404.7K |
| Derived metrics | |||
| Operating margin | -154.6% | -1677.0% | — |
| Net margin | -119.5% | -1359.8% | — |
| Return on equity | -160.4% | -139.4% | — |
| Cash conversion ratio | 0.45× | 0.57× | — |
| Other reported items | |||
| Adjustments For Depreciation Expense | DKK 2.1M | DKK 2.1M | — |
| Adjustments For Finance Costs | DKK 1.5M | DKK 568.1K | — |
| Cash | -DKK 795.4K | -DKK 415.0K | DKK 2.9M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | DKK 3.6M | -DKK 256.0K | — |
| Cost of Merchandise Sold | DKK 5.2M | DKK 153.7K | — |
| Deferred Tax Assets | DKK 12.3M | DKK 7.5M | DKK 226.5K |
| Finished Goods | DKK 963.2K | DKK 2.7M | DKK 1.2M |
| Increase Decrease In Cash and Cash Equivalents | -DKK 380.4K | -DKK 3.3M | — |
| Increase Decrease In Working Capital | -DKK 1.7M | -DKK 3.5M | — |
| Interest Paid Classified As Financing Activities | DKK 1.5M | DKK 568.1K | — |
| Investments In Subsidiaries | DKK 4.1M | DKK 0 | DKK 0 |
| Issued Capital | DKK 1.1M | DKK 801.0K | DKK 708.6K |
| Liabilities | DKK 36.4M | DKK 25.9M | DKK 27.4M |
| Longterm Deposits | DKK 57.0K | DKK 106.7K | DKK 82.2K |
| Noncurrent Provisions | DKK 4.8M | DKK 0 | DKK 329.9K |
| Other Comprehensive Income | -DKK 6.3M | DKK 0 | — |
| Other Current Payables | DKK 3.5M | DKK 1.6M | DKK 710.9K |
| Other Current Receivables | DKK 225.1K | -DKK 85.1K | DKK 1.5M |
| Other Income Expense From Subsidiaries Jointly Controlled Entities and Associates | -DKK 459.1K | DKK 0 | — |
| Payments For Development Project Expenditure | DKK 3.4M | DKK 2.2M | — |
| Payments For Share Issue Costs | DKK 6.3M | DKK 0 | — |
| Retained Earnings | -DKK 4.5M | DKK 1.7M | DKK 16.3M |
| Trade and Other Current Payables To Trade Suppliers | DKK 8.9M | DKK 5.1M | DKK 504.2K |
| Trade and Other Current Receivables Due From Related Parties | DKK 0 | DKK 0 | DKK 0 |
| Work In Progress | DKK 0 | DKK 0 | DKK 64.4K |
Every line item above is a fact tagged in CS MEDICA a/s's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (DKK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.